Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Consolidative Allogenic Hematopoietic Cell Transplantation Vs. Watch and Wait Strategy for B-Cell Acute Lymphoblastic Leukemia Patients with Early Loss of B-Cell Aplasia after Chimeric Antigen Receptor T-Cell Therapy

Sergi Camarillas, Anna Alonso-Saladrigues, Agueda Molinos Quintana, Víctor Navarro, Blanca Herrero-Velasco, Mario Sánchez-Salinas, Berta González-Martínez, Ana Africa Martin Lopez, Anna Torrent, Julia Marsal, Juan Luis Reguera, Gloria Iacoboni, Antonio Pérez-Martínez, Susana Rives, Pere Barba

Blood (2024) 144 (Supplement 1): 5898.

https://doi.org/10.1182/blood-2024-205932

Published: 2024

Journal Articles

Treatment with Siltuximab for Short Term Complications after Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Retrospective Analysis

Jose M. Sanchez-Pina, Pablo Silva, Lucía López-Corral, Anabelle Chinea, Ana Africa Martin Lopez, Nuria Martinez-Cibrian, Rafael Hernani, Victor Noriega, Silvia Filaferro, Pascual Balsalobre, Maria Calbacho, Antonio Pérez-Martínez, Pere Barba, Mi Kwon

Blood (2024) 144 (Supplement 1): 7220.

https://doi.org/10.1182/blood-2024-207963

Published: 2024

Journal Articles

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 112.

https://doi.org/10.1182/blood-2024-201946

Published: 2024

Journal Articles

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Blood (2024) 144 (Supplement 1): 67.

https://doi.org/10.1182/blood-2024-204264

Published: 2024

Journal Articles

Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 2105.

https://doi.org/10.1182/blood-2024-203054

Published: 2024

Journal Articles

Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial

Blood (2024) 144 (Supplement 1): 962.

https://doi.org/10.1182/blood-2024-205124

Published: 2024

Journal Articles

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Jaime Roman Diaz, Saurabh Dahiya, Francesca Emily Sillito, Maeve O'Reilly, Kai Rejeski, Veit L. Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick Locke, Jay Y. Spiegel, Najla H. Al Ali, Zachary Thompson, Jongphil Kim, Rami S. Komrokji, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7239.

https://doi.org/10.1182/blood-2024-201666

Published: 2024

Journal Articles

Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r/r AML

Marion Subklewe, Nicolas Boissel, Stephan Mielke, Pere Barba, Elisa Sala, Eric Deconinck, Olivia Fiere, Jonathan Jaeger, Chloe Vasseghi, Marina Deschamps, Christophe Ferrand, Edouard De Dreuzy, Richard Sainson, Jens Hasskarl

Blood (2024) 144 (Supplement 1): 2883.2.

https://doi.org/10.1182/blood-2024-203204

Published: 2024

Journal Articles

Long-Term Outcomes and Late Complications of Allogeneic Stem Cell Transplant with CD34+ Positive Selection in Adults with Acute Leukaemia and Myelodysplastic Syndrome: A Single-Centre Study

Elisa Roldan, Alba Puyuelo, Sergi Camarillas, Olga Salamero, Ana Perez Gonzalez, Maria Laura Fox, Felix Lopez, Maria Sola, Pere Barba, Guillermo Orti, David Valcarcel

Blood (2024) 144 (Supplement 1): 3545.

https://doi.org/10.1182/blood-2024-205956

Published: 2024

Journal Articles

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 471.

https://doi.org/10.1182/blood-2024-205809

Published: 2024

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Autologous Chimeric Antigen Receptor T-Cell Therapy: A Meta-Analysis of 1,154 Patients Included in Clinical Trials

Pere Barba, Victor Navarro Garces, Sergi Camarillas, Cecilia Carpio, Mario Sánchez-Salinas, Samantha Feijoo, Maria Landwehr, Francesc Bosch, Gloria Iacoboni, Guillermo Villacampa

Blood (2024) 144 (Supplement 1): 4186.

https://doi.org/10.1182/blood-2024-205176

Published: 2024

Journal Articles

Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

Blood (2024) 144 (Supplement 1): 2333.

https://doi.org/10.1182/blood-2024-206032

Published: 2024

Journal Articles

Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Gloria Iacoboni, Pere Barba, Irma Khvedelidze, Maud Ngoya, Paolo Corradini, Pierre Sesques, Marion Subklewe, Maria Gomes Da Silva, Gilles Crochet, Jarosław Dybko, Izaskun Zeberio, Alejandro Martín García-Sancho, Tom van Meerten, Maeve O'Reilly, Bertram Glass, Ana Maria Sureda Balari, Peter Dreger, Olivier Hermine, Ali Bazarbachi

Blood (2024) 144 (Supplement 1): 3656.

https://doi.org/10.1182/blood-2024-205389

Published: 2024

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2024-205671

Published: 2024

Journal Articles

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Blood (2024) 144 (Supplement 1): 1437.

https://doi.org/10.1182/blood-2024-207954

Published: 2024

Journal Articles

Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL

Blood (2024) 144 (Supplement 1): 1714.

https://doi.org/10.1182/blood-2024-211459

Published: 2024

Journal Articles

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Blood (2024) 144 (Supplement 1): 3414.

https://doi.org/10.1182/blood-2024-205005

Published: 2024

Journal Articles

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Blood (2024) 144 (3): 334–338.

https://doi.org/10.1182/blood.2024024526

Published: 2024

Includes: Supplemental data

Journal Articles

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Jeremy S. Abramson, Aravind Ramakrishnan, Ana Alfonso Pierola, Ira Braunschweig, Guillaume Cartron, Catherine Thieblemont, Jose A. Pérez-Simón, Pere Barba, Peter A. Riedell, Carlos Solano, Thomas Gastinne, Alexandra LaCroce, Denise Thomas, Camille Poirot, Sarah Meadows, Kathryn J. Newhall, Daniel J. Lee, Mark G. Frattini, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 2110.

https://doi.org/10.1182/blood-2023-186570

Published: 2023

Journal Articles

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Blood (2023) 142 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2023-186510

Published: 2023

NARROW

Consolidative Allogenic Hematopoietic Cell Transplantation Vs. Watch and Wait Strategy for B-Cell Acute Lymphoblastic Leukemia Patients with Early Loss of B-Cell Aplasia after Chimeric Antigen Receptor T-Cell Therapy

Treatment with Siltuximab for Short Term Complications after Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Retrospective Analysis

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r/r AML

Long-Term Outcomes and Late Complications of Allogeneic Stem Cell Transplant with CD34+ Positive Selection in Adults with Acute Leukaemia and Myelodysplastic Syndrome: A Single-Centre Study

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Clinical Outcomes of Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Autologous Chimeric Antigen Receptor T-Cell Therapy: A Meta-Analysis of 1,154 Patients Included in Clinical Trials

Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only